A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells.

FFPE MALDI cytospin imaging mass spectrometry sample preparation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Feb 2023
Historique:
received: 24 12 2022
revised: 27 01 2023
accepted: 31 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

Sample processing of formalin-fixed specimens constitutes a major challenge in molecular profiling efforts. Pre-analytical factors such as fixative temperature, dehydration, and embedding media affect downstream analysis, generating data dependent on technical processing rather than disease state. In this study, we investigated two different sample processing methods, including the use of the cytospin sample preparation and automated sample processing apparatuses for proteomic analysis of multiple myeloma (MM) cell lines using imaging mass spectrometry (IMS). In addition, two sample-embedding instruments using different reagents and processing times were considered. Three MM cell lines fixed in 4% paraformaldehyde were either directly centrifuged onto glass slides using cytospin preparation techniques or processed to create paraffin-embedded specimens with an automatic tissue processor, and further cut onto glass slides for IMS analysis. The number of peaks obtained from paraffin-embedded samples was comparable between the two different sample processing instruments. Interestingly, spectra profiles showed enhanced ion yield in cytospin compared to paraffin-embedded samples along with high reproducibility compared to the sample replicate.

Identifiants

pubmed: 36765932
pii: cancers15030974
doi: 10.3390/cancers15030974
pmc: PMC9913598
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Association for Cancer Research
ID : IG24449
Organisme : Italian Ministry of Health
ID : GR-2016-02361523

Références

BMC Biol. 2020 Mar 26;18(1):35
pubmed: 32216777
Haematologica. 2019 Dec;104(12):2456-2464
pubmed: 30948485
Blood Cancer J. 2021 Feb 1;11(2):24
pubmed: 33563895
Mass Spectrom Rev. 2022 Jul 11;:e21795
pubmed: 35815718
Brief Funct Genomic Proteomic. 2005 May;4(1):69-75
pubmed: 15975266
Virchows Arch A Pathol Anat Histopathol. 1983;402(2):195-201
pubmed: 6420986
Proteomics Clin Appl. 2019 Jan;13(1):e1800034
pubmed: 30216696
Int J Oncol. 2015 Mar;46(3):893-906
pubmed: 25482502
Proteomics. 2018 Jan;18(2):
pubmed: 29236356
Br J Haematol. 2022 Aug;198(4):641-653
pubmed: 35514140
Chin Med J (Engl). 2015 Apr 20;128(8):1108-13
pubmed: 25881608
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33435632
Phys Chem Chem Phys. 2017 Jul 5;19(26):17143-17155
pubmed: 28636681
Proteomics Clin Appl. 2019 Jan;13(1):e1800045
pubmed: 30471204
J Proteome Res. 2014 Feb 7;13(2):844-54
pubmed: 24256566
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019064
Clin Lab Med. 2021 Jun;41(2):309-324
pubmed: 34020766
Cancers (Basel). 2019 Jul 16;11(7):
pubmed: 31315220
Life (Basel). 2022 Jul 12;12(7):
pubmed: 35888125
Proteomics. 2004 Mar;4(3):562-77
pubmed: 14997480
Leukemia. 2017 Nov;31(11):2426-2434
pubmed: 28344315
Pol Arch Intern Med. 2017 Jun 30;127(6):392-400
pubmed: 28546528
Dis Markers. 2002;18(2):99-105
pubmed: 12364816
Proteomics. 2004 Aug;4(8):2476-95
pubmed: 15274142
Sci Rep. 2016 Oct 07;6:34949
pubmed: 27713570
Clin Cancer Res. 2006 Sep 1;12(17):5142-50
pubmed: 16951232
Life (Basel). 2022 Mar 03;12(3):
pubmed: 35330118
Adv Cancer Res. 2017;134:283-290
pubmed: 28110655
Curr Opin Mol Ther. 2000 Dec;2(6):643-50
pubmed: 11249741
Proteomics Clin Appl. 2019 Jan;13(1):e1800035
pubmed: 30035857
J Cancer Res Clin Oncol. 2016 Jun;142(6):1191-200
pubmed: 26945985
Int J Mol Med. 2011 Mar;27(3):417-21
pubmed: 21174066
Histochem Cell Biol. 2008 Sep;130(3):421-34
pubmed: 18618129
Anal Chem. 1997 Dec 1;69(23):4751-60
pubmed: 9406525
Cancer Metab. 2017 Aug 29;5:7
pubmed: 28855983
Am J Cancer Res. 2022 Jul 15;12(7):3280-3293
pubmed: 35968359
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769070
Clin Chem. 2016 Oct;62(10):1334-44
pubmed: 27540026
Nat Protoc. 2007;2(8):1987-97
pubmed: 17703210
Leukemia. 2018 Sep;32(9):1948-1957
pubmed: 29487387

Auteurs

Rita Casadonte (R)

Proteopath GmbH, 54296 Trier, Germany.

Jörg Kriegsmann (J)

Proteopath GmbH, 54296 Trier, Germany.
Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500 Krems, Austria.

Mark Kriegsmann (M)

Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, Heidelberg University, 69120 Heidelberg, Germany.

Roberta Torcasio (R)

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
Laboratory of Cellular and Molecular Cardiovascular Pathophysiology, Department of Biology, Ecology and Earth Sciences (DiBEST), University of Calabria, Arcavacata di Rende, 87036 Cosenza, Italy.

Maria Eugenia Gallo Cantafio (ME)

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.

Giuseppe Viglietto (G)

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.

Nicola Amodio (N)

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.

Classifications MeSH